Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRXFree Report) from a hold rating to a buy rating in a research report report published on Friday morning.

Several other equities research analysts have also recently issued reports on the company. Citigroup started coverage on Catalyst Pharmaceuticals in a report on Thursday, March 14th. They issued a buy rating and a $27.00 price objective on the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. HC Wainwright reiterated a buy rating and issued a $26.00 price objective on shares of Catalyst Pharmaceuticals in a report on Monday, June 3rd. Bank of America started coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a buy rating and a $23.00 price objective on the stock. Finally, TheStreet upgraded Catalyst Pharmaceuticals from a c+ rating to a b rating in a report on Tuesday, March 12th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of Buy and an average price target of $26.71.

Get Our Latest Stock Report on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Stock Down 0.9 %

NASDAQ:CPRX opened at $15.62 on Friday. Catalyst Pharmaceuticals has a 52 week low of $11.48 and a 52 week high of $17.50. The stock has a market capitalization of $1.84 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 1.38 and a beta of 0.73. The stock’s 50-day moving average price is $15.65 and its 200-day moving average price is $15.23.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 EPS for the quarter, meeting analysts’ consensus estimates of $0.31. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The firm had revenue of $98.51 million for the quarter, compared to analysts’ expectations of $97.24 million. Sell-side analysts expect that Catalyst Pharmaceuticals will post 1.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the transaction, the insider now directly owns 124,433 shares of the company’s stock, valued at approximately $2,045,678.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Gary Ingenito sold 80,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $16.16, for a total transaction of $1,292,800.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $830,478.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 25,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the sale, the insider now directly owns 124,433 shares in the company, valued at approximately $2,045,678.52. The disclosure for this sale can be found here. Insiders have sold 152,656 shares of company stock valued at $2,459,376 in the last ninety days. 11.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its position in shares of Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 720 shares during the period. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares during the period. State Board of Administration of Florida Retirement System raised its position in Catalyst Pharmaceuticals by 4.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 1,290 shares during the period. Mutual of America Capital Management LLC raised its position in Catalyst Pharmaceuticals by 9.7% in the first quarter. Mutual of America Capital Management LLC now owns 19,241 shares of the biopharmaceutical company’s stock valued at $307,000 after purchasing an additional 1,701 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Catalyst Pharmaceuticals by 15.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 1,719 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.